STUDY DESIGN: A prospective, randomized, double-blind study comparing high-dose @entity1667 with placebo. OBJECTIVES: To evaluate the efficacy of high-dose @entity1667 when administered within 8 hours after @entity7125 . SUMMARY OF BACKGROUND DATA: @entity7125 often results in chronic symptoms. The management of @entity7125 is controversial, and pharmacologic therapy has received little evaluation. In recent reports, dysfunction of the central nervous system has been indicated in several cases. @entity1667 administered within 8 hours after the injury to @entity1 with acute @entity1566 has been demonstrated to improve the outcome. This procedure was also adopted in a randomized study of cases of @entity7125 in car accidents. METHODS: Forty @entity1 , 22 @entity1 and 18 @entity1 with a mean age of 35 years (range, 19-65), were included in the study, 20 in each of two groups. They were treated for @entity7125 , which they had sustained in car accidents. The @entity1 were enrolled if their diagnoses were complete and treatment had begun within 8 hours after injury. Disabling symptoms severe enough to prevent the @entity1 from returning to work, number of sick days before and after injury, and sick-leave profile after injury were used as parameters for the evaluation of the effects of the treatment. Baseline demographic data were controlled for when statistical analysis had been performed. RESULTS: At the follow-up examination 6 months after initial treatment, there was a significant difference in disabling symptoms between the actively treated @entity1 and the placebo group (P = 0.047), total number of sick days (P = 0.01), and sick-leave profile (P = 0.003). CONCLUSIONS: The results of this study indicate that acute treatment with high-dose @entity1667 may be beneficial in preventing extensive sick leave after @entity7125 . However, the number of @entity1 studied was small, and therefore further prospective, controlled studies are needed.

High-dose @entity1667 prevents extensive sick leave after XXXX . A prospective, randomized, double-blind study.

@entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone', 'Methylprednisolone'] @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'men'] @entity7125 :: ('MESH:D014911', 'Disease') :: ['whiplash injuries', 'whiplash injury', 'Whiplash injury'] @entity1566 :: ('MESH:D013119', 'Disease') :: ['spinal cord injury']
@entity7125 :: (MESH:D014911,Disease) :: ['whiplash injury']
